The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy
University of Insubria · Cliniques Universitaires Saint-Luc · +10 more institutions
Abstract
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing…
Citation impact
- FWCI
- 61.11
- Percentile
- 100%
- References
- 130
Authors
10- LBLuigi BartalenaCorresponding
University of Insubria
- LBLelio Baldeschi
Cliniques Universitaires Saint-Luc, UCLouvain
- KBKostas Boboridis
Aristotle University of Thessaloniki
- AEAnja Eckstein
Essen University Hospital
- GJGeorge J. Kahaly
Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz
Topics & keywords
- Medicine
- Watchful waiting
- Graves' ophthalmopathy
- Graves' disease
- Rituximab
- Thyroid
- Surgery
- Disease
- Good health and well-being